• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

炎症性肠病患者管理中的共同决策。

Shared decision-making in the management of patients with inflammatory bowel disease.

机构信息

Department of Gastroenterology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100730, China.

出版信息

World J Gastroenterol. 2022 Jul 14;28(26):3092-3100. doi: 10.3748/wjg.v28.i26.3092.

DOI:10.3748/wjg.v28.i26.3092
PMID:36051346
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9331519/
Abstract

The rapid progress of research into inflammatory bowel disease (IBD) has resulted in increasingly more treatment options. Different options have different advantages and disadvantages, and the preferences of patients may also differ. If patients can be invited to the formulation of medical decision-making, their compliance and satisfaction would be improved, thus possibly achieving better therapeutic results. The present review aims to summarize the current literature on shared decision-making (SDM) in the management of IBD, with the goal of promoting the application of SDM.

摘要

炎症性肠病(IBD)研究的快速进展带来了越来越多的治疗选择。不同的选择有不同的优缺点,患者的偏好也可能不同。如果能邀请患者参与医疗决策的制定,将提高他们的依从性和满意度,从而可能获得更好的治疗效果。本文旨在总结目前关于 IBD 管理中共享决策(SDM)的文献,以促进 SDM 的应用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5e6/9331519/1a94136f4c0b/WJG-28-3092-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5e6/9331519/1a94136f4c0b/WJG-28-3092-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f5e6/9331519/1a94136f4c0b/WJG-28-3092-g001.jpg

相似文献

1
Shared decision-making in the management of patients with inflammatory bowel disease.炎症性肠病患者管理中的共同决策。
World J Gastroenterol. 2022 Jul 14;28(26):3092-3100. doi: 10.3748/wjg.v28.i26.3092.
2
Patients' perception of their involvement in shared treatment decision making: Key factors in the treatment of inflammatory bowel disease.患者对自身参与共同治疗决策的认知:炎症性肠病治疗中的关键因素。
Patient Educ Couns. 2018 Feb;101(2):331-339. doi: 10.1016/j.pec.2017.07.028. Epub 2017 Jul 25.
3
Patients' views of shared decision making in inflammatory bowel disease: a survey in China.炎症性肠病患者对共同决策的看法:中国的一项调查。
BMC Med Inform Decis Mak. 2021 Dec 6;21(1):340. doi: 10.1186/s12911-021-01702-8.
4
Gastroenterologists' Views of Shared Decision Making for Patients with Inflammatory Bowel Disease.胃肠病学家对炎症性肠病患者共同决策的看法。
Dig Dis Sci. 2015 Sep;60(9):2636-45. doi: 10.1007/s10620-015-3675-z. Epub 2015 May 5.
5
Patients' preferences regarding shared decision-making in the treatment of inflammatory bowel disease: results from a patient-empowerment study.患者对炎症性肠病治疗中共同决策的偏好:一项患者赋权研究的结果。
Digestion. 2010;81(2):113-9. doi: 10.1159/000253862. Epub 2010 Jan 9.
6
Decision making about anti-TNF therapy: A pilot trial of a shared decision-making intervention.关于抗 TNF 治疗的决策:一项共享决策干预的试点试验。
Patient Educ Couns. 2022 May;105(5):1075-1081. doi: 10.1016/j.pec.2021.09.030. Epub 2021 Sep 30.
7
Novel Statistical Approach to Determine Inflammatory Bowel Disease: Patients' Perspectives on Shared Decision Making.用于确定炎症性肠病的新型统计方法:患者对共同决策的看法。
Patient. 2016 Feb;9(1):79-89. doi: 10.1007/s40271-015-0126-z.
8
Optimizing Selection of Biologics in Inflammatory Bowel Disease: Development of an Online Patient Decision Aid Using Conjoint Analysis.优化炎症性肠病生物制剂的选择:使用联合分析开发在线患者决策辅助工具。
Am J Gastroenterol. 2018 Jan;113(1):58-71. doi: 10.1038/ajg.2017.470. Epub 2017 Dec 5.
9
Shared decision making in inflammatory bowel disease: helping patients understand the tradeoffs between treatment options.炎症性肠病的共同决策:帮助患者了解治疗方案之间的权衡。
Gut. 2012 Mar;61(3):459-65. doi: 10.1136/gutjnl-2011-300988. Epub 2011 Dec 20.
10
What are the Unmet Needs and Most Relevant Treatment Outcomes According to Patients with Inflammatory Bowel Disease? A Qualitative Patient Preference Study.炎症性肠病患者的未满足需求和最相关的治疗结局有哪些?一项定性的患者偏好研究。
J Crohns Colitis. 2023 Apr 3;17(3):379-388. doi: 10.1093/ecco-jcc/jjac145.

引用本文的文献

1
Immune dysregulation in ulcerative colitis: pathogenic mechanisms and therapeutic strategies of traditional Chinese medicine.溃疡性结肠炎中的免疫失调:中医发病机制与治疗策略
Front Cell Dev Biol. 2025 Jun 5;13:1610435. doi: 10.3389/fcell.2025.1610435. eCollection 2025.
2
Factors Influencing Decision-Making Preferences Among Patients with Inflammatory Bowel Disease: A Cross-Sectional Study in China.影响炎症性肠病患者决策偏好的因素:一项中国的横断面研究。
Patient Prefer Adherence. 2025 Apr 12;19:1047-1057. doi: 10.2147/PPA.S517510. eCollection 2025.
3
Unmet Healthcare Needs Among People with Inflammatory Bowel Disease: A Canadian Cross-Sectional Population-Representative Study.

本文引用的文献

1
Assessing Patient Decision-Making on Biologic and Small-Molecule Therapies in Inflammatory Bowel Diseases: Insights From a Conjoint Analysis in the United States, Canada, and the United Kingdom.评估炎症性肠病患者对生物制剂和小分子治疗药物的决策:来自美国、加拿大和英国的联合分析见解。
Inflamm Bowel Dis. 2021 Oct 18;27(10):1593-1601. doi: 10.1093/ibd/izaa311.
2
Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab.在接受维得利珠单抗或乌司奴单抗治疗的炎症性肠病患者中,联合治疗并未提高临床或内镜缓解率。
Clin Gastroenterol Hepatol. 2021 Jul;19(7):1366-1376.e2. doi: 10.1016/j.cgh.2020.07.012. Epub 2020 Jul 12.
3
炎症性肠病患者未满足的医疗需求:一项加拿大横断面人群代表性研究。
Dig Dis Sci. 2025 Apr 2. doi: 10.1007/s10620-025-09015-w.
4
Effects of self-acupressure on quality of life and abdominal pain severity among patients with inflammatory bowel disease: A randomized sham-controlled trial.自我穴位按压对炎症性肠病患者生活质量和腹痛严重程度的影响:一项随机假对照试验。
J Ayurveda Integr Med. 2025 Mar 25;16(2):101080. doi: 10.1016/j.jaim.2024.101080.
5
Patients' and gastroenterologists' preferences regarding outcomes and medication attributes in ulcerative colitis.溃疡性结肠炎患者和胃肠病学家对治疗结果及药物属性的偏好
Ann Gastroenterol. 2025 Mar-Apr;38(2):174-181. doi: 10.20524/aog.2025.0944. Epub 2025 Feb 25.
6
Understanding the therapeutic toolkit for inflammatory bowel disease.了解炎症性肠病的治疗方法。
Nat Rev Gastroenterol Hepatol. 2025 Jan 31. doi: 10.1038/s41575-024-01035-7.
7
Impact of exercise on outcomes among Chinese patients with Crohn's disease: a mixed methods study based on social media and the real world.运动对中国克罗恩病患者结局的影响:基于社交媒体和真实世界的混合方法研究。
BMC Gastroenterol. 2024 Nov 29;24(1):441. doi: 10.1186/s12876-024-03533-z.
8
Framework of IBD Care Delivery Across Ages.IBD 全年龄段照护提供模式框架。
J Crohns Colitis. 2024 Oct 30;18(Supplement_2):ii55-ii66. doi: 10.1093/ecco-jcc/jjae093.
9
Identification and prioritization of patient-centred strategies to enhance IBD-related care for older adults: a modified Delphi approach.确定并优先排序以患者为中心的策略,以加强对老年炎症性肠病患者的护理:一种改良的德尔菲法。
J Can Assoc Gastroenterol. 2024 Jul 6;7(5):384-392. doi: 10.1093/jcag/gwae021. eCollection 2024 Oct.
10
Shared decision-making and detection of comorbidities in an online acromegaly consultation with and without the Acromegaly Disease Activity Tool ACRODAT using the simulated person approach.使用模拟患者方法的在线肢端肥大症咨询中,有无 Acromegaly Disease Activity Tool ACRODAT 对共同决策和共病检测的影响。
Pituitary. 2024 Oct;27(5):545-554. doi: 10.1007/s11102-024-01460-6. Epub 2024 Sep 25.
Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications.
联合生物和免疫调节治疗优于单药治疗,可降低炎症性肠病相关并发症的风险。
J Crohns Colitis. 2020 Oct 5;14(10):1354-1363. doi: 10.1093/ecco-jcc/jjaa050.
4
Head-to-head trials in inflammatory bowel disease: past, present and future.炎症性肠病的头对头试验:过去、现在和未来。
Nat Rev Gastroenterol Hepatol. 2020 Jun;17(6):365-376. doi: 10.1038/s41575-020-0293-9. Epub 2020 Apr 17.
5
A Comprehensive Review and Update on the Pathogenesis of Inflammatory Bowel Disease.炎症性肠病发病机制的全面综述和更新。
J Immunol Res. 2019 Dec 1;2019:7247238. doi: 10.1155/2019/7247238. eCollection 2019.
6
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.维得利珠单抗与阿达木单抗治疗中重度溃疡性结肠炎的疗效比较。
N Engl J Med. 2019 Sep 26;381(13):1215-1226. doi: 10.1056/NEJMoa1905725.
7
A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease.炎症性肠病的诊断、预防及治疗方法综述
J Med Life. 2019 Apr-Jun;12(2):113-122. doi: 10.25122/jml-2018-0075.
8
In the absence of head-to-head trials, what do real world studies tell us about the comparative effectiveness of biologics in Crohn's disease.在缺乏头对头试验的情况下,真实世界研究告诉了我们什么有关生物制剂在克罗恩病中的比较疗效的信息。
Best Pract Res Clin Gastroenterol. 2019 Feb-Apr;38-39:101619. doi: 10.1016/j.bpg.2019.05.006. Epub 2019 May 29.
9
The Role of Early Biologic Therapy in Inflammatory Bowel Disease.早期生物治疗在炎症性肠病中的作用。
Inflamm Bowel Dis. 2019 Nov 14;25(12):1896-1905. doi: 10.1093/ibd/izz059.
10
Induction and maintenance treatment of inflammatory bowel disease: A comprehensive review.炎症性肠病的诱导和维持治疗:全面综述。
Autoimmun Rev. 2019 May;18(5):439-454. doi: 10.1016/j.autrev.2019.03.002. Epub 2019 Mar 4.